【摘要】 目的 系统评价口服中药对癌症患者化疗后癌因性疲乏的疗效与安全性。方法 全面检索有关口服中药治疗癌症患者化疗后癌因性疲乏的临床研究，使用(ROB2)风险评估工具对纳入的文献进行质量评价，使用Stata15软件进行Meta分析。结果 共纳入30篇文献，合并分析结果显示口服中药联合化疗治疗化疗后癌因性疲乏更有效[RR=1.59,95%CI=(1.40-1.80),P<0.01)];Piper评分更低：[SMD=-1.98,CI=(-2.60,-1.36),P<0.01];生活质量更高[SMD=2.04,95%CI=(1.09,2.98),P<0.01]。安全性分析发现，口服中药联合化疗治疗不良反应发生率更低，[RR=0.57,95%CI=(0.48,0.67),P<0.01)]。结论 结果表明，口服中药联合化疗与单一治疗相比，可以显著的改善癌症患者癌因性疲乏的各种结局指标，说明口服中药治疗癌症患者化疗后癌因性疲乏具有其临床价值。更多还原

【Abstract】 Objective: To systematically evaluate the effectiveness and safety of oral Chinese medicine on cancer-related fatigue after chemotherapy in cancer patients. Methods: Clinical studies related to oral Chinese medicine treatment of cancer patients with cancer-related fatigue after chemotherapy were comprehensively searched. The quality of included literature was evaluated using(ROB2) risk assessment tool, and meta-analysis was performed using Stata15 software. Results: A total of 30 literature were included. The combined analysis showed that oral Chinese medicine combined with chemotherapy was more effective in treating cancer-related fatigue after chemotherapy [RR=1.59, 95%CI=(1.40-1.80), P<0.01]. Piper score was lower, [SMD=-1.98, CI=(-2.60,-1.36), P<0.01]. Quality of life was higher, [SMD=2.04, 95%CI=(1.09, 2.98), P<0.01]. Safety analysis showed that oral Chinese medicine combined with chemotherapy had a lower incidence of adverse reactions [RR=0.57, 95%CI=(0.48, 0.67), P<0.01)]. Conclusion: The results show that oral Chinese medicine combined with chemotherapy can significantly improve various outcome indexes of cancer-related fatigue in cancer patients when compared with single therapy, indicating that oral Chinese medicine has its clinical value in treating cancer-related fatigue after chemotherapy.更多还原